DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Sequist LV, Besse B, Lynch TJ et al.
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
J Clin Oncol 2010;
28: 3076-3083
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.